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Background: We have previously identified kinase suppressor of ras-1 (KSR1) as a potential regulatory gene in breast cancer.
KSR1, originally described as a novel protein kinase, has a role in activation of mitogen-activated protein kinases. Emerging
evidence has shown that KSR1 may have dual functions as an active kinase as well as a scaffold facilitating multiprotein complex
assembly. Although efforts have been made to study the role of KSR1 in certain tumour types, its involvement in breast cancer
remains unknown.
Methods: A quantitative mass spectrometry analysis using stable isotope labelling of amino acids in cell culture (SILAC) was
implemented to identify KSR1-regulated phosphoproteins in breast cancer. In vitro luciferase assays, co-immunoprecipitation as
well as western blotting experiments were performed to further study the function of KSR1 in breast cancer.
Results: Of significance, proteomic analysis reveals that KSR1 overexpression decreases deleted in breast cancer-1 (DBC1)
phosphorylation. Furthermore, we show that KSR1 decreases the transcriptional activity of p53 by reducing the phosphorylation of
DBC1, which leads to a reduced interaction of DBC1 with sirtuin-1 (SIRT1); this in turn enables SIRT1 to deacetylate p53.
Conclusion: Our findings integrate KSR1 into a network involving DBC1 and SIRT1, which results in the regulation of p53
acetylation and its transcriptional activity.
Kinase suppressor of ras-1 (KSR1), initially described more than 15
years ago as a novel protein kinase in the Ras-Raf pathway
(Kornfeld et al, 1995; Therrien et al, 1995) is an essential
scaffolding protein that co-ordinates the assembly of the
mitogen-activated protein kinase (MAPK) complex, consisting of
the MAPK kinase MEK and the extracellular signal-regulated
kinase (ERK) to facilitate activation of MEK and thus ERK
(Kolesnick and Xing, 2004; Zafrullah et al, 2009; Goettel et al,
2011). KSR1 has been extensively referred to as a pseudokinase,
because of its lack of a key catalytic residue (Zhang et al, 2012).
However, emerging evidence suggests that KSR1 functions as an
active kinase as well as a scaffold protein. Using recombinant wild-
type KSR1, different groups have shown that KSR1 is capable of
directly phosphorylating Raf-1 and MEK1 (Zafrullah et al, 2009;
Goettel et al, 2011; Hu et al, 2011). On the other hand, crystal
structure analysis suggests a direct interaction between KSR and
Raf that enables KSR1 to regulate Raf activation independent of its
catalytic activity (Rajakulendran et al, 2009). Such findings add
complexity to the simple view of ERK spatio-temporal pathway
control and identify pseudokinases such as KSR1 as potential targets.
Given the role of KSR1 in the Ras–Raf–MAPKs cascade,
intensive efforts have focused on Ras-dependent cancers. For
instance, recent studies reported that KSR1 regulates the
proliferative and oncogenic potential of cells and inhibition of
KSR1 abrogates Ras-dependent pancreatic cancer growth (Xing
et al, 2003; Kortum and Lewis, 2004). Similarly, KSR1 is required
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for tumour formation in a skin cancer mouse model (Lozano et al,
2003). As Ras mutations are rare in breast cancer, the involvement of
KSR1 may not depend on the canonical Ras–Raf–MAPKs pathway.
Using a short interfering RNA (siRNA) kinome screen, we identified
KSR1 as a novel regulator of the transcriptional activity of oestrogen
receptor alpha (ERa; Giamas et al, 2011). Moreover, we show that
KSR1 expression is significantly correlated with overall and disease-
free survival in patients with breast cancer (our unpublished data).
However, its biologic functions in this setting have remained
unexplored, as are its major partner proteins and pathways including
those connected to p53, which we implicate here.
The p53 tumour suppressor is well known to have a central role
in cell growth arrest, apoptosis and cellular response to genotoxic
stress (Levine, 1997; Vogelstein et al, 2000). Its transcriptional
activity is highly regulated by post-transcriptional modifications
including acetylation (Brooks and Gu, 2003; Tang et al, 2008).
Previous data demonstrate that deleted in breast cancer 1 (DBC1)
directly interacts and negatively regulates the deacetylase SIRT1
resulting in an increase of p53 acetylation (Kim et al, 2008; Zhao
et al, 2008). Furthermore, phosphorylation of DBC1 is necessary
for its interaction with SIRT1, while it inhibits the activity of SIRT1
in response to DNA damage (Yuan et al, 2012; Zannini et al, 2012).
Herein, we present a KSR1-regulated phosphoproteomic profile
in breast cancer cells using a stable isotope labelling of amino acids
in cell culture (SILAC) approach. Furthermore, we identify a role
of KSR1 in the regulation of p53 transactional activity by reducing
its acetylation via the modulation of DBC1–SIRT1 interaction.
MATERIALS AND METHODS
SILAC cell culture. SILAC dialysed calf serum and custom
Dulbecco’s modified Eagle’s medium (DMEM) mediums contain-
ing either unlabelled [12C6,
14N4]-arginine (Arg) and [
12C6]-lysine
(Lys) (R0K0 –‘light’) or labelled [13C6,
15N4]-Arg and [
13C6]-Lys
(R10K8 –‘heavy’) were purchased from Dundee Cell Products
(Dundee, UK). MCF7 cells were grown in these custom DMEM
mediums along with 10% dialysed fetal calf serum (FCS) and 1% of
antibiotics (penicillin and streptomycin). The cells that were grown
for at least seven passages were used for this experiment.
Protein digestion and peptide fractionation. Equal amounts of
protein from unlabelled and labelled samples were combined
before protein digestion. Briefly, samples were reduced in 10mM
dithiothreitol (DTT) and alkylated in 50mM iodoacetamide before
boiling in loading buffer, and then separated by one-dimensional
sodium dodecyl sulphate (SDS)–PAGE 4–12% Bis-Tris Novex
mini-gel from Invitrogen (Paisley, UK) and visualised by colloidal
Coomassie staining from Invitrogen. The entire protein gel lanes
were excised and cut into 10 slices each. Every gel slice was subjected
to in-gel digestion with trypsin overnight at 37 1C. The resulting
tryptic peptides were extracted by formic acid (1%) and acetonitile,
lyophilised in a speedvac and resuspended in 1% formic acid.
Protein digestion and phosphopeptide enrichment. FASP
procedure was performed as previously described (Wisniewski et al,
2009). In all, 500ul FASP 1 (8M urea, 20mM DDT in 100mM Tris/HCL
pH 8.5) was added to B2mg protein lysate to dilute SDS
concentration and transferred to a Vivacon 500, 30k MWCO HY
filter from Sartorius Stedim Biotech (Epsom, UK). The sample was
buffer exchanged using FASP 1 several times by spinning the tube
at 7000 g to remove detergents. The protein lysate was concen-
trated by centrifugation and diluted in FASP 2 (100mM Tris/HCl
pH 8.5) ready for trypsin digestion. The sample was reduced using
50mM fresh IAA in FASP 2 in the dark for 30min. Lysates were
spun down to remove excess IAA and buffer exchanged into FASP
3 (100mM triethyl ammonium bicarbonate). Trypsin was dissolved
in FASP 3 to give a 1 : 200 enzyme to protein ratio and added in a
volume of at least 100 ml for 4–6 h. This was repeated with fresh
trypsin for a further overnight incubation. Lysates were spun
down and washed with 0.5 M NaCl and 150 ml 10% TFA added to
reduce the pH. A standard desalting procedure was used
(Thingholm et al, 2006).
Hydrophilic interaction chromatography (HILIC) fractionation:
A TSKgel Amide-80 separation column with a TSKgel Amide
guard column was used for HILIC separation of FASP peptides.
Buffer A: 80% ACN, 0.1% formic acid and buffer B: 0.1% formic
acid was used for the gradient at a flow rate of 0.6mJmin–1. The
sample was separated into 45 fractions, collected 2mins per vial
and dried using a speed vac.
TiO2 enrichment was performed as previously described
(Thingholm et al, 2006). TiO2 beads were washed and
re-suspended in buffer B at 50 mg ml–1 and added to tubes to give
1mg per tube. The sample was re-suspended in loading buffer,
added to beads and incubated at RT for 20min. After washing,
using buffers A and B samples were eluted using aliquots of 0.5%
NH4OH. Elutions were pooled and 10 ml of 20% FA added to
adjust the pH. Samples were dried and re-suspended in 1% FA.
Mass spectrometry methods. Trypsin-digested peptides were
separated using an Ultimate 3000 RSLC nanoflow LC system
from Thermo Scientific (Cramlington, UK). On average 0.5 mg was
loaded with a constant flow of 5 ml min–1 onto an Acclaim
PepMap100 nanoViper C18 trap column (100mm inner-diameter,
2 cm; Thermo Scientific). After trap enrichment, peptides were
eluted onto an Acclaim PepMap RSLC nanoViper, C18 column
(75 mm, 15 cm; Thermo Scientific) with a linear gradient of 2–40%
solvent B (80% acetonitrile with 0.08% formic acid) over 65min
with a constant flow of 300 nlmin–1. The HPLC system was
coupled to a linear ion trap Orbitrap hybrid mass spectrometer
(LTQ-Orbitrap Velos, Thermo Scientific) via a nano electrospray
ion source (Thermo Scientific). The spray voltage was set to 1.2 kV,
and the temperature of the heated capillary was set to 250 1C. Full-
scan MS survey spectra (m/z 335–1800) in profile mode were
acquired in the Orbitrap with a resolution of 60 000 after
accumulation of 1 000 000 ions. The 15 most intense peptide ions
from the preview scan in the Orbitrap were fragmented by
collision-induced dissociation (normalised collision energy, 35%;
activation Q, 0.250; and activation time, 10ms) in the LTQ after
the accumulation of 10 000 ions. Maximal filling times were
1000ms for the full scans and 150ms for the MS/MS scans.
Precursor ion charge state screening was enabled, and all
unassigned charge states as well as singly charged species were
rejected. The lock mass option was enabled for survey scans to
improve mass accuracy. Data were acquired using the Xcalibur
software from Thermo Scientific.
Quantification and bioinformatics analysis. The raw mass
spectrometric data files obtained for each experiment were collated
into a single quantitated data set using MaxQuant (Cox and Mann,
2008) and the Andromeda search engine software (Cox et al, 2011).
Enzyme specificity was set to that of trypsin, allowing for cleavage
N-terminal to proline residues and between aspartic acid and
proline residues. Other parameters used were: (i) variable
modifications, methionine oxidation, protein N-acetylation, gln
- pyro-glu; (ii) fixed modifications, cysteine carbamidomethyla-
tion; (iii) database: target-decoy human MaxQuant (ipi.HU-
MAN.v3.68); (iv) heavy labels: R6K4 and R10K8; (v) MS/MS
tolerance: FTMS – 10 p.p.m., ITMS – 0.6Da; (vi) maximum
peptide length, 6; (vii) maximum missed cleavages, 2; (viii)
maximum of labelled amino acids, 3; and (ix) false discovery rate,
1%. Peptide ratios were calculated for each arginine-containing
and/or lysine-containing peptide as the peak area of labelled
arginine/lysine divided by the peak area of non-labelled arginine/
lysine for each single-scan mass spectrum. Peptide ratios for all
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arginine-containing and lysine-containing peptides sequenced for
each protein were averaged. Data are normalised using 1/median
ratio value for each identified protein group per labelled sample.
Cell lines, reagents, antibodies and plasmids. MCF7, ZR75-1,
SKBR3, MDA-MB-231 (MDA231) and p53þ /þ HCT116 cells were
maintained in DMEM supplemented with 10% FCS and 1% penicillin/
streptomycin/glutamine. All cells were incubated at 37 1C in
humidified 5% CO2. FuGENE HD transfection reagent was obtained
from Roche (Burgess Hill, UK). siKSR1 were purchased from Qiagen
(Crawley, UK) and verified. Plasmids containing human wild-type
KSR1 (pCMV6-KSR1) and empty vector (pCMV6-vector) were
obtained from OriGene (Cambridge, UK). Mutant KSR1 R502M
was generated using QuikChange Site-Directed Mutagenesis Kit were
from Stratagene (Stockport, UK) and confirmed by plasmid sequence.
MCF7-parental and MCF7-KSR1 stable cells were generated by
transfection of either pCMV6-vector or pCMV6-KSR1 in MCF7 cells
and selected in the presence of G418 (1mgml–1). KSR1 overexpression
was confirmed by RT–qPCR and western blotting. Etoposide was
purchased from Sigma Aldrich (Gillingham, UK). The Dual-Glo
Luciferase Assay System was purchased from Promega (Southampton,
UK). The following antibodies were used: KSR1 rabbit polyclonal from
Cell Signaling (Hitchin, UK), anti-Flag mouse monoclonal (Sigma
Aldrich), p53 mouse monoclonal DO-1 from Santa Cruz (Wiltshire,
UK), acetylated-p53 and phospho-p53 Ser15 rabbit polyclonal (Cell
Signaling), SIRT1 rabbit polyclonal (Santa Cruz), DBC1 and phospho-
DBC1 Thr454 rabbit polyclonal (Cell Signaling) and b-actin mouse
monoclonal from Abcam (Cambridge, UK). The following p53-target
gene promoter–reporter constructs previously described (Vikhanskaya
et al, 2007) were a kind gift from Professor Kanaga Sabapathy: AIP-1-
luciferase (luc), IGFBP3-luc, R2-luc and cyclinG1-luc. The renilla
luciferase reporter vector (pRL-TK) was purchased from Promega.
Protein extraction and western blotting. NP40 lysis buffer
(50mM Tris-HCl, pH 8.0, 150mM NaCl, 10% (v/v) glycerol, 1%
NP40, 5mM DTT, 1mM EDTA, 1mM EGTA, 50 mM leupeptin and
30 mgml–1 aprotinin) was used to extract whole-cell lysates. Cell
pellets were mixed thoroughly with NP40 lysis buffer, and then
incubated in ice for 15min before centrifuging at 15 000 r.p.m. for
15min at 4 1C. Nuclear and cytoplasmic extracts were prepared
from whole-cell lysis using NE-PER Nuclear and Cytoplasmic
Extraction Kit (Thermo Scientific). Protein concentration was
measured by the bicinchoninic acid (BCA) protein assay from
Pierce (Epsom, UK). Lysates were heated with 5 SDS sample
buffer at 95 1C for 5min before they were loaded to 10% SDS–
PAGE. Samples were then transferred to Hybond ECL super
nitrocellulose membranes from GE Healthcare (Little Chalfont,
UK). Subsequently, the membranes were blocked in TBS contain-
ing 0.1% (v/v) Tween20 and 5% (w/v) non-fat milk for 1 h. The
primary antibodies were probed with membranes overnight at
4 1C. The membranes were then washed three times in TBS/Tween
for 15min following incubation with HRP-conjugated secondary
antibodies (1 : 3000 dilution) for 60min. The membranes were
then washed three times again and were detected with enhanced
chemiluminescence (ECL). Films were developed using a Konica
SRX-1001A X-ray developer (Banbury, UK). Alternatively, mem-
branes were incubated with IRDye donkey anti-mouse or donkey
anti-rabbit secondary antibodies for 60min and visualised by
Odyssey Fc Imaging System from LI-COR (Cambridge, UK).
RNA extraction and RT–qPCR. RNeasy kit (Qiagen) was used to
isolate total RNA. Reverse transcription was performed using high-
capacity cDNA reverse transcription kit from Applied Biosystems
(Warrington, UK). RT–qPCR analysis was performed on a
7900HT Thermocycler (Applied Biosystems) using TaqMan
mastermix and primers for TP53 and GAPDH cDNAs, purchased
from Applied Biosystems.
Luciferase reporter assay. In all, 8 104 per well MCF7 cells were
seeded into 24-well plate and transfection was performed using
FuGENE HD transfection reagent according to the manufacturer’s
instructions. Cells were transfected with different p53 constructs,
and pCMV6-KSR1 or pCMV6-vector and together with renilla
luciferase reporter vector (pRL-TK). Cell lysates were collected
after 24-h transfection and firefly and renilla luciferase activities
were measured by the Dual-Glo Luciferase Assay kit as per the
manufacturer’s protocols described. The transcriptional activity of
various p53 constructs were determined by firefly luciferase activity
and normalised against renilla luciferase activity, which was served
as control for transfection efficiency.
Immunofluorescence staining. MCF7 cells seeded on glass
coverslips in 6 cm dishes were transfected with pCMV6-KSR1 or
pCMV6-Vector using FuGENE HD. Cells were fixed in 4% w/v
paraformaldehyde at 37 1C for 15min, permeabilised with 0.1%
Triton-X for 10min and incubated in immune-fluorescent
blocking buffer (10% AB-serum in PBS) for 1 h, followed by
incubation with p53 antibody (DO-1). After washing with PBS,
coverslips were incubated for 45min at 37 1C with anti-mouse-IgG
Alexa Fluor  555 antibody (Invitrogen). DNA was visualised by
DAPI staining. Cells were examined on an Axiovert-200 laser
scanning inverted microscope from Zeiss (Welwyn Garden City,
UK) as previously described (Giamas et al, 2011).
Cell proliferation assay. Sulphorhodamine B (SRB) assay was
performed to determine the growth of breast cancer cell lines in
96-well plates. After siRNA knockdown of KSR1 at indicated time
points, plates were collected for the following protocol. Cells were
fixed by adding 100 ml per well of ice-cold 40% trichloroacetic acid
(TCA) to each culture for 1 h and incubated in the fridge. Plates
were then washed  5 times in running tap water (allow the water
to fill wells indirectly). Cells were stained with 100 ml of 0.4% (w/v)
SRB from Sigma Aldrich in 1% acetic acid for 30min and plates
were washed five times in 1% acetic acid and left to air dry
overnight. On the day of plate reading, bound dye was solubilised
by adding 100 ml of 10mM Tris base to all the wells and plates were
measured at 492 nm using Tecan microplate reader (Reading, UK).
Neddylation assay. MCF7 cells plated on 15 cm dishes were
transfected using FuGENE HD with 8 mg pcDNA3-HA-NEDD8
from Addgene (Cambridge, MA, USA), 8 mg pCMV6-KSR1 or 8 mg
pCMV6-vector constructs as indicated. After 24 h, cells were lysed
in radio-immunoprecipitation assay (RIPA) buffer (Sigma Aldrich)
supplemented with protease inhibitors. Total protein was quanti-
fied by the BCA assay (Pierce). In all, 2 mg mouse IgG or p53 (DO-
1) was pre-incubated with protein agarose beads for 2 h to form IP
matrix complex (ImmunoCruz IP/WB Optima C System, Santa
Cruz). In total, 2mg protein lysate was added into the beads and
was incubated on a rotator overnight at 4 1C. Beads were washed
with RIPA buffer for three times and were heated in SDS loading
buffer. Neddylated p53 were detected by western blot using p53-
specific DO-1 antibody or NEDD8 antibody (Cell Signaling) as
described before (Xirodimas et al, 2004; Abida et al, 2007).
Statistical analysis. Each experiment was repeated at least three
times. Student’s t-test was two-sided at a 0.05 significance level and
performed using SPSS 16.0 statistical software (SPSS Inc., Chicago,
IL, USA).
RESULTS
Phosphoproteomics analysis of KSR1-regulated proteins using
SILAC. In order to obtain the KSR1-regulated phosphoproteome
profile, a necessary step to understand its integrated signalling
pathways in breast cancer, we first performed a quantitative
proteomic analysis.
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Here, MCF7 cells were maintained for seven cell divisions in
either R0K0 ‘light’ medium, containing unlabelled [12C6,
14N4]-
arginine (Arg) and [12C6]-lysine (Lys) amino acids, or in R10K8
‘heavy’ medium, containing labelled [13C6,
15N4]-Arg and [
13C6,
15N2]-Lys. Labelled cells were then transfected with either the
pCMV6 vector (R0K0, control) or with a pCMV6-KSR1 plasmid
(R10K8) that encodes for the full-length KSR1. After 24 h, proteins
were extracted, mixed 1 : 1, separated on SDS–PAGE, trypsin-
digested, fractionated and analysed by LC-MS/MS using Max-
Quant software (Cox and Mann 2008; Figure 1A).
We identified a total of 2504 proteins out of which 2032 were
quantified (false discovery rate o1%). Similarly, we found 1409
phosphopeptides from 891 phosphoproteins out of which 1165
phosphopeptides from 812 phosphoproteins were quantified. After
normalisation, we determined the phosphorylation vs total protein
level ratio between control and KSR1-overexpressed samples.
Based on our data, we obtained information about the phospho-
rylation change of 379 potential sites that correspond to 240
proteins, as several proteins had more than one potential
phosphorylation sites. Among these modulated sites, 341 phos-
phoserine (pS), 37 phosphothreonine (pT) and 1 phosphotyrosine
(pY) sites were included (Supplementary Excel File 1).
Surprisingly, only 3 out of the 379 identified phospho-sites were
induced 450% while most of them (233 out of 379) were actually
decreased (o50%) after KSR1 overexpression. These data partly
support the characterisation of KSR1 as a pseudokinase, emphasising
its primary role as a scaffold protein not a kinase. The values from
total and phosphorylated proteins were plotted to create a graph
showing the log2 normalised ‘total proteins’ vs the log2 ‘phosphory-
lated proteins’ ratios (Figure 1B).
Ontology analysis of differentially regulated KSR1 phosphoproteins.
We then performed gene ontology (GO) analysis and classification
(using the ‘Panther’ software; Mi et al, 2013) to assign the
KSR1-regulated phosphoproteome according to (i) molecular
functions, (ii) biological processes and (iii) cellular components
(Figure 1C). We found significant enrichment for GO molecular
functions terms related to binding (GO: 0005488), catalytic activity
(GO: 0003824), structural molecule activity (GO: 0005198), as well
as transcription regulator (GO: 0003824) and enzyme regulator
(GO: 0030234) activities. Our phosphoproteomics analysis facili-
tated the identification of biological processes associated with cell
cycle (GO: 0007049) and communication (GO: 0007154) along
with metabolic (GO: 0008152), cellular (GO: 009987) and
transport (GO: 0006810) processes. Finally, regarding the localisa-
tion of the identified KSR1-regulated phosphoproteins, there was a
similar distribution between membrane/cytoplasmic and nuclear
cell components, resulting from the direct and indirect effects of
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Figure 1. Identification of KSR1-regulated phosphoproteome in breast cancer cells. (A) Experimental schematic outline of SILAC experiment.
(B) Scatter plot comparison of phosphosite ratios quantified from control vs KSR1-overexpressed MCF7 cells. (C) Gene ontology (GO)
Classification of the KSR1-regulated phosphoproteome in MCF7 cells according to molecular functions, biological processes and cellular
compartmentalisation.
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KSR1 abundance. This is by far the first ontology analysis of KSR1-
regulated phosphoprotein profile in cancer, which will for sure
enable extensive study of its functions in signalling pathways other
than the canonical Ras–Raf–MAPKs cascades.
Phosphoproteomics analysis reveals a downregulation of
phospho-DBC1 by KSR1. Further examination of the identified
KSR1-regulated phosphoproteins unveiled that some of these proteins
have been previously implicated in the development of breast
cancer. For instance, androgen-induced proliferation inhibitor
(APRIN), a protein phosphorylated by ATM (ataxia telangiectasia-
mutated) and ATR (ataxia telangiectasia and Rad3-related) kinases,
was described as a BRCA2-interacting protein required for genome
integrity and a predictor of outcome in response to chemotherapy
in breast cancer (Matsuoka et al, 2007; Brough et al, 2012). Rho
GTPase-activating protein 35 (ARHGAP35) was shown to be
phosphorylated by breast tumour kinase (Brk) leading to RhoA
inactivation, Ras activation and promotion of breast cancer growth
and migration (Shen et al, 2008). Phosphorylation of Hsp27 was
correlated with HER-2/neu status and lymph node positivity in
breast cancer, and phosphorylated Hsp27 was also linked to
invasiveness and drug resistance (Zhang et al, 2007; Fujita et al,
2011). Histone deacetylase 1/Sin3A complex phosphorylation has
been linked to ERa expression and hormonal therapy resistance in
breast cancer cells (De Amicis et al, 2011).
Interestingly, among the most significantly KSR1-regulated
phosphorylated proteins, was DBC1, whose involvement in the
regulation of p53 activity via SIRT1 has been described previously
(Kim et al, 2008; Zhao et al, 2008). Taking into consideration the
importance of p53 in breast cancer, we then assessed the
connection between KSR1 and p53 activity in vitro.
KSR1 regulates the transcriptional activity of p53. We first
examined the effects of KSR1 on p53 transcriptional activity by
performing luciferase reporter assays using various p53-dependent
gene promoter constructs (including p53-R2, p53-AIP1, p53-
IGFBP3 and p53-CYCLIN G1). MCF7 cells were co-transfected
with either pCMV6 or pCMV6-KSR1 plasmids and each individual
p53-dependent promoter construct, in the presence or absence of
etoposide, which can induce p53 activity. Interestingly, the
luciferase activity of all four different p53-regulated genes was
significantly repressed after overexpression of KSR1, suggesting an
oppressive role of KSR1 on p53 activation (basal levels and after
etoposide treatment; Figure 2A). As expected, silencing of KSR1
resulted in a marked increase in the activity of p53-dependent
promoter genes (Figure 2B). These results suggest a potential
involvement of KSR1 in p53 transcriptional activity regulation.
KSR1 does not affect the mRNA, protein, subcellular localisation
and neddylation levels of p53. In order to investigate the
potential mechanism resulting in the downregulation of p53
transcriptional activity, we initially evaluated the p53 gene and
protein expression after KSR1 overexpression. RT–qPCR and
western blotting analyses did not reveal any changes in the p53
mRNA and protein levels, respectively, after KSR1 transient
overexpression in MCF7 cells (Figure 3A). Similarly, no change
in p53 protein levels was observed in MCF7 stably overexpressing
KSR1 cells comparing with MCF7 parental cells (Figure 3A). As
the nuclear localisation of p53 is essential for its activity, we
examined whether KSR1 could affect p53 compartmentalisation.
Immunofluorescence and subcellular protein fractionation did not
reveal any cytoplasmic translocation of p53 upon KSR1 transient
overexpression (Figure 3B). Moreover, it has been recently
reported that neddylation of p53 can inhibit its transcriptional
activity (Xirodimas et al, 2004; Abida et al, 2007). However, our
neddylation assay did not show any significant changes following
KSR1 overexpression ruling out neddylation as the reason for the
observed p53 decreased activity (Figure 3C).
KSR1 decreases p53 acetylation by reducing phosphorylation of
DBC1 resulting in impaired DBC1–SIRT1 interaction. Post-
translational modifications of p53 such as phosphorylation and
acetylation are essential for p53 activity in response to genotoxic
stress (Brooks and Gu, 2003; Tang et al, 2008). To examine effects
of KSR1 on phospho-p53 and acetylated-p53, cells were transfected
with pCMV6 or pCMV6-KSR1 plasmids in the presence of
etoposide or doxorubicin. Although the phosphorylation levels of
p53 (Ser15) did not change, interestingly the acetylated-p53 was
reduced after KSR1 overexpression upon either etoposide
(Figure 4A) or doxorubicin (Supplementary Figure 1) treatment.
Similar results were confirmed in several other breast cancer cell
lines (including ZR75-1 and SKBR3) and one colon cancer cell line
HCT116 (Supplementary Figure 1).
It is already known that SIRT1 functions as an NAD-dependent
p53 deacetylase that affects p53 activation (Vaziri et al, 2001; Tang
et al, 2008). In addition, DBC1 can interact with and negatively
regulate SIRT1 resulting in increased p53 acetylation (Kim et al,
2008; Zhao et al, 2008). Taking this potential link into
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consideration, we decided to investigate the effects of KSR1 on
these two proteins.
Total SIRT1 levels were not affected by KSR1 upregulation
(Figure 4A). Based on the SILAC data regarding the effects of
KSR1 on the phosphorylation of DBC1 and the association
between DBC1 and SIRT1, we performed western blotting of
phospho-DBC1 (Thr454) revealing a decrease in the phospho-
rylation levels in basal and etoposide-induced conditions
(Figure 4A). Consistently, KSR1 silencing rescued the abolished
acetylation of p53 after etoposide treatment (Figure 4B).
Moreover, knock-down of KSR1 did not alter the total
proteins of SIRT1 and DBC1, but increased DBC1 phosphoryla-
tion at Thr454 (Figure 4B). These data further validate our
SILAC results and allow KSR1 to integrate into a known network
of p53 acetylation regulation involving phospho-DBC1 and
SIRT1.
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To further demonstrate that KSR1 regulates p53 acetylation
through DBC1, we studied the effects of KSR1 on p53 acetylation
after DBC1 knockdown upon etoposide treatment in MCF7 cells.
As shown in Figure 4C, western blotting experiments revealed that
acetylated p53 was consistently increased after silencing of KSR1,
whereas no change in p53 acetylation was observed after knocking
down both KSR1 and DBC1 upon etoposide treatment. This
suggests that KSR1 regulates p53 acetylation through DBC1, as
depleting DBC1 undermines the effect of KSR1 on acetylated p53.
Moreover, to examine whether the effect of KSR1 on DBC1
depends on its catalytic activity, we generated a KSR1 mutant
(KSR1/R502M) that encompasses a key amino-acid mutation
(arginine to methionine) within its kinase domain resulting in
impaired catalytic activity (Laurent et al, 2004). Consistently, wild-
type KSR1 decreased pDBC1, whereas mutant KSR1/R502M
sustained pDBC1 levels in comparison with the control
(Figure 4D). This result suggests that an intact catalytic domain
of KSR1 is essential for regulating DBC1 phosphorylation.
Phosphorylation of DBC1, induced by genotoxic stress, creates
binding sites and enhances the interaction between SIRT1 and
DBC1 (Yuan et al, 2012; Zannini et al, 2012), which subsequently
undermines the deacetylase activity of SIRT1 on p53. For this
reason, we tested whether KSR1 affects the stress-induced SIRT1–
DBC1 interaction. As shown in Figure 4E, upon etoposide
treatment, the interaction between SIRT1 and DBC1, determined
by co-immunoprecipitation (IP), was undermined after KSR1
overexpression in MCF7, which allows SIRT1 to interact more with
p53 resulting in declined p53 acetylation.
KSR1 is important for breast cancer proliferation and its
expression is altered in breast cancer. To study whether KSR1
affects breast cancer growth in vitro, cell proliferation assay was
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performed in four different breast cancer cell lines. As shown in
Figure 5, knockdown of KSR1 significantly reduced breast cancer
cell growth in MCF7, ZR75-1, SKBR3 and MDA231 after six days,
showing an important role of KSR1 in breast cancer cell
proliferation. This is also supported by further examination of
KSR1 expression in breast tumour tissues. Oncomine analysis
(Rhodes et al, 2004) was conducted to study the levels of KSR1 in
normal breast and cancer tissues from TCGA Breast database.
Indeed, KSR1 abundance is varied between normal breast and
various breast carcinomas, including invasive ductal breast
carcinoma and invasive lobular breast carcinoma (Figure 6).
Specifically, KSR1 expression is significantly upregulated in
invasive ductal breast carcinoma, lobular breast carcinoma and
invasive breast carcinoma.
DISCUSSION
KSR1 was originally identified as a novel protein kinase
evolutionarily conserved in Drosophila and Caenorhabditis elegans
functioning between Ras and Raf in the Ras–Raf–MAPKs
signalling pathway (Kornfeld et al, 1995; Therrien et al, 1995).
However, mammalian KSR1 has been extensively referred as a
pseudokinase, because of the mutation in the lysine residue in the
catalytic domain, which is essential for its kinase activity (Zhang
et al, 2012). Later, the role of KSR1 as a scaffolding protein was
discovered. Murine KSR1 was first reported to cooperate with
activated Ras to facilitate MAPK kinases activation thus stimulat-
ing Xenopus oocyte maturation and cellular transformation
(Therrien et al, 1996). At the same time, the idea of KSR1 as an
active kinase was described from the finding that TNF-a and
ceramide were shown to significantly increase KSR1 autopho-
sphorylation and its capacity to phosphorylate and activate Raf-1
(Zhang et al, 1997). Therefore, emerging evidence suggests dual
function of KSR1 as an active kinase as well as a scaffold protein
(Rajakulendran et al, 2009; Hu et al, 2011). Moreover, KSR1 has
been previously shown as an oncogene in Ras-dependent cancers,
such as pancreatic and lung carcinomas (Xing et al, 2003; Kortum
and Lewis, 2004). However, its biological functions and modulated
signalling pathways in breast cancer have remained undefined.
In this study, we performed a global comparative proteomic
analysis and for the first time reveal the complex KSR1-regulated
phosphoproteome in MCF7 breast cancer cells. Various new
KSR1-regulated proteins and signalling networks that KSR1 is
involved in were identified. Notably, our phosphoproteomic
analysis showed that the majority (233 out of 379) of the
identified phospho-sites were actually reduced after KSR1 over-
expression in comparison with a small number of increased
phosphorylations (3 out of the 379), suggesting its primary role as
a scaffold protein not a kinase at least in this context.
Interestingly, none of the previously described proteins including
MEK and ERK in the canonical Ras–Raf–MAPKs pathways have
been identified in our study. The possible explanation could be
that the Ras mutations are very rare in breast cancer (Adjei,
2001). Indeed, our recent work has also shown no significant
alteration in phosphorylation of the main components in the
Ras–Raf–MAPKs cascades upon overexpressing or silencing
KSR1 (unpublished work). Moreover, the KSR1-regulated phos-
phoproteins identified in this study illustrated a much more
extensive view of KSR1 involved biological functions, including
cell cycle, metabolism and apoptosis. Notably, some phospho-
proteins have been shown to have vital roles in multiple aspects of
breast cancer. For example, APRIN was reported as a BRCA2-
interacting protein essential for genome integrity and associated
with chemotherapy response in breast cancer (Matsuoka et al,
2007; Brough et al, 2012), whereas ARHGAP35 was shown to be
important in breast cancer growth and migration (Shen et al,
2008). Phospho-Hsp27 was related to invasiveness and drug
resistance in breast cancer (Zhang et al, 2007; Fujita et al, 2011).
Most importantly, the KSR1-regulated phosphoproteomic
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analysis has identified phospho-DBC1 as a potential connection
to its modulation of p53 transcriptional activity here.
Deleted in breast cancer-1 was previously reported to be
involved in regulating p53 acetylation (Kim et al, 2008; Zhao et al,
2008), which is indispensable for p53 transcriptional activity (Tang
et al, 2008). Therefore, our work further investigated the effects of
KSR1 on p53 transcriptional activity, as well as the potential
mechanism on KSR1-mediated regulation of p53 transcriptional
activity, including p53 acetylation. Luciferase assays using different
p53-dependent gene promoter constructs showed that KSR1
overexpression suppressed p53 transcriptional activity in the
absence or presence of etoposide, whereas the opposite results
were observed after silencing of KSR1, indicating a regulatory role
of KSR1 in p53 activity. Mechanistic study demonstrated that
overexpression of KSR1 had no effect on p53 mRNA and total
protein levels, as well as subcellular localisation, phosphorylation
and neddylation, which are all potentially involved in p53 activity
modulation.
As expected, KSR1 overexpression reduced the acetylation of
p53, whereas silencing of KSR1 rescued the decreased p53
acetylation in the absence or presence of etoposide, suggesting
that KSR1 is involved in regulating p53 acetylation. It has already
been shown that DBC1 can interact with and negatively regulate
SIRT1, a NAD-dependent p53 deacetylase, resulting in increased
p53 acetylation (Kim et al, 2008; Zhao et al, 2008). Moreover,
phospho-DBC1, induced by genotoxic stress, is competent to
create binding sites and enhance the interaction between SIRT1
and DBC1, which subsequently undermines deacetylase activity of
SIRT1 on p53 (Yuan et al, 2012; Zannini et al, 2012). Consistently,
we demonstrated that KSR1 overexpression decreases the phos-
pho-DBC1 levels, whereas KSR1 silencing increases DBC1
phosphorylation. This provides us an explanation to the observed
effects of KSR1 on p53 acetylation and activity. Similar results were
obtained after overexpression or silencing KSR1 in different breast
cancer cell lines including ZR75-1 and SKBR3. Further co-IP
experiments proved that overexpression of KSR1 attenuates the
interaction of SIRT1–DBC1, which therefore allows SIRT1 to
interact more with p53 resulting in decreased p53 acetylation. Our
data herein are consistent with previous reports and in combina-
tion with our SILAC analyses enable KSR1 to integrate into a
known network together with DBC1 and SIRT1 on regulation of
p53 acetylation.
However, more evidence is still needed to elucidate the
mechanism of KSR1 on modulating DBC1 phosphorylation. The
work from Zannini et al (2012) demonstrated that ATM/ATR can
directly phosphorylate DBC1 on Thr454 upon DNA damage.
Phosphorylated DBC1 bound to and inhibited SIRT1, leading to
the separation of the SIRT1-p53 complex and an increase of p53
acetylation. Moreover, another group indicated that protein kinase A
and AMP-activated protein kinase was capable of inducing the
dissociation of SIRT1 from its endogenous inhibitor DBC1,
resulting in an alteration in downstream effects (Nin et al, 2012).
Therefore, whether the effect of KSR1 on DBC1 phosphorylation is
through ATM/ATR kinases or alternative pathways requires
further investigation.
Collectively, our SILAC analyses of the KSR1-regulated
phosphoproteome profile in cancer cells demonstrate its involve-
ment in multiple biological and molecular processes as well as
intricate signalling pathways. The identification of novel KSR1-
regulated proteins will shed light on new KSR1-modulated
signalling pathways implicated in breast cancer. In this work, we
propose a model (Figure 4F) where in cancer cells with basal levels
of KSR1, phosphorylated DBC1 directly interacts with SIRT1 and
reduces its deacetylase activity resulting in p53 activation and gene
expression initiation. However, in KSR1-transduced cells, KSR1
suppresses DBC1 phosphorylation, which undermines the direct
interaction between DBC1 and SIRT1. This in turn allows SIRT to
decrease p53 acetylation, which eventually inhibits p53 transcrip-
tional activity. Our study provides a new insight on the role of
KSR1 in p53 regulation and unveils an interesting mechanism for
its function in breast cancer development.
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